Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
 

Unrivalled AMNOG Process Knowledge

Gain relevant insights from our summary analysis and our evaluation of all AMNOG resolutions. more >>

Every Resolution Reviewed in Detail

The AMNOG monitor includes detailed analyses of every sinlge benefit assessment since 2011. more >>

Reimbursement Price Trends

See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

Discontinuations

 Keep track of benefit-assessed medicinal products no longer available in Germany.. more >>

 

Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement. 

Contact us for more information! >>

 

Dear readers of the AMNOG Monitor,

With a total of more than 130 early benefit assessment procedures in 2021, the pharmaceutical industry has been showing its innovative strength and the G-BA is demonstrating its ability to act even during a pandemic.

We, too, have implemented a whole range of new options for analyses in the AMNOG Monitor. We have already familiarised our customers with these new possibilities in various training courses. Please feel free to contact us if you need training or have any questions. We are constantly striving to make the AMNOG Monitor user-friendlier and welcome your suggestions for further development.

In September 2021, another 16 G-BA resolutions on early benefit assessments were passed, so that a total of 634 procedures are now completed. The results of the new resolutions are shown in the table below.

Resolutions September 2021

Nivolumab (15) Opdivo® Melanoma, adjuvant therapy 100% Hint for considerable additional benefit
Natrium-Zirkonium-Cyclosilikat Lokelma® Hyperkalemia 100% no additional benefit
Remdesivir Veklury® COVID-19, ≥ 12 years, additional oxygen supply 34% Hint for minor additional benefit
Avatrombopag (2) Doptelet® Thrombocytopenia in chronic liver disease 100% no additional benefit
Avatrombopag Doptelet® Immune thrombocytopenia (ITP) 100% no additional benefit
Fostemsavir Rukobia® HIV infection, multi-resistant 100% no additional benefit
Pembrolizumab (16) Keytruda® Hodgkin-Lymphoma (HL), pretreated patients, ≥ 3 years 46% Hint for considerable additional benefit
Pembrolizumab (15) Keytruda® Urothelial carcinoma (UC), first-line 100% no additional benefit
Pembrolizumab (14) Keytruda® Colorectal carcinoma with MSI-H or dMMR, first line 87% Hint for minor additional benefit
Bedaquilin (3) Sirturo® Multi-resistant pulmonary tuberculosis 100% Hint for non-quantifiable additional benefit
Imlifidase Idefirix® Desensitization after kidney transplantation 100% Hint for non-quantifiable additional benefit
Fedratinib Inrebic® Myelofibrosis (MF) 100% Hint for non-quantifiable additional benefit
Tucatinib Tukysa® Mamma carcinoma (BC), pretreated, combination with Trastuzumab and Capecitabin 100% Hint for considerable additional benefit
Selpercatinib Retsevmo® Non-small cell lung cancer (NSCLC), RET fusion+, pre-treated 100% no additional benefit
Selpercatinib (2) Retsevmo® Medullary thyroid cancer (MTC), pretreated, > 12 years 100% no additional benefit
Selpercatinib (3) Retsevmo® Medullary thyroid carcinoma (MTC), pretreated 100% no additional benefit